Should I buy or sell Petros Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Petros Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PTPI shares. View PTPI analyst ratings or view top-rated stocks .

What is Petros Pharmaceuticals' stock price target for 2024?

1 equities research analysts have issued 1 year target prices for Petros Pharmaceuticals' stock. Their PTPI share price targets range from $4.00 to $4.00. On average, they predict the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 473.1% from the stock's current price. View analysts price targets for PTPI or view top-rated stocks among Wall Street analysts .

How have PTPI shares performed in 2024?

Petros Pharmaceuticals' stock was trading at $1.41 at the beginning of the year. Since then, PTPI stock has decreased by 50.5% and is now trading at $0.6979. View the best growth stocks for 2024 here .

Are investors shorting Petros Pharmaceuticals?

Petros Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 146,200 shares, an increase of 65.4% from the March 15th total of 88,400 shares. Based on an average daily volume of 1,080,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 3.6% of the shares of the company are sold short. View Petros Pharmaceuticals' Short Interest .

When is Petros Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our PTPI earnings forecast .

How were Petros Pharmaceuticals' earnings last quarter?

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) announced its earnings results on Monday, April, 1st. The company reported ($2.17) EPS for the quarter. The firm had revenue of ($0.36) million for the quarter. Petros Pharmaceuticals had a negative net margin of 181.87% and a negative trailing twelve-month return on equity of 68.90%.

When did Petros Pharmaceuticals' stock split?

Petros Pharmaceuticals shares reverse split on Wednesday, November 30th 2022. The 1-10 reverse split was announced on Wednesday, November 30th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Petros Pharmaceuticals?

Shares of PTPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PTPI

Petros Pharmaceuticals (PTPI) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free PTPI Stock Alerts

$0.68

-0.02 (-2.56%)

(As of 12:29 PM ET)

Compare

Today's Range: $0.67
▼
$0.70
50-Day Range: $0.69
▼
$1.72
52-Week Range: $0.64
▼
$9.54

Volume: 112,257 shs
Average Volume: 985,027 shs
Market Capitalization: $4.68 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

Get Petros Pharmaceuticals alerts:

Petros Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 473.1% Upside
$4.00 Price Target
Short Interest: Healthy
3.57% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.27
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.05 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Petros Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Petros Pharmaceuticals has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.57% of the float of Petros Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Petros Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Petros Pharmaceuticals has recently increased by 65.38%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Petros Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Petros Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PTPI.

1.8

News and Social Media Coverage

News Sentiment
Petros Pharmaceuticals has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Petros Pharmaceuticals this week, compared to 0 articles on an average week.
Search Interest
Only 1 people have searched for PTPI on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Petros Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
36.38% of the stock of Petros Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 12.34% of the stock of Petros Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Petros Pharmaceuticals is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Petros Pharmaceuticals is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Petros Pharmaceuticals has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Petros Pharmaceuticals Stock (NASDAQ:PTPI)

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, PreBoost, VenoSeal, penile injections, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

PTPI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PTPI Stock News Headlines

April 18, 2024 | markets.businessinsider.com

Positive Outlook for Petros Pharmaceuticals: Buy Rating Affirmed Amidst FDA Advances and Promising Stendra Developments

April 18, 2024 | americanbankingnews.com

Petros Pharmaceuticals (NASDAQ:PTPI) Trading Down 2.1%

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 2, 2024 | markets.businessinsider.com

Petros Pharma Stock Down, Despite Positive Results For Stendra Study

April 2, 2024 | investorplace.com

PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023

March 20, 2024 | finanznachrichten.de

Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider

March 6, 2024 | morningstar.com

Petros Pharmaceuticals Inc Ordinary Shares PTPI

February 14, 2024 | finance.yahoo.com

Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

January 30, 2024 | uk.investing.com

Petros Pharmaceuticals Inc (PTPI)

January 24, 2024 | finance.yahoo.com

Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch

January 17, 2024 | finance.yahoo.com

Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC Switch

December 14, 2023 | markets.businessinsider.com

Buy Rating on Petros Pharmaceuticals Amid Positive User Experience and Strategic FDA Pathway Compliance

December 12, 2023 | benzinga.com

Petros Pharma Stock (NASDAQ:PTPI) Insider Trades

December 12, 2023 | finance.yahoo.com

Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor’s (rosuvastatin) OTC Switch Technology Provider

December 12, 2023 | finance.yahoo.com

Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status

December 9, 2023 | nasdaq.com

Maxim Group Initiates Coverage of Petros Pharmaceuticals (PTPI) with Buy Recommendation

December 9, 2023 | benzinga.com

Petros Pharma Stock (NASDAQ:PTPI), Analyst Ratings, Price Targets, Predictions

December 8, 2023 | realmoney.thestreet.com

Petros Pharmaceuticals initiated with bullish view at Maxim

December 7, 2023 | morningstar.com

Petros Pharmaceuticals Inc Ordinary Shares

December 5, 2023 | finanznachrichten.de

Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's OTC Switch Technology Provider

December 5, 2023 | finance.yahoo.com

Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's (rosuvastatin) OTC Switch Technology Provider

October 30, 2023 | finance.yahoo.com

Petros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)

October 19, 2023 | finance.yahoo.com

Following Encouraging FDA Feedback Petros Pharmaceuticals Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA

October 4, 2023 | finanznachrichten.de

Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential OTC STENDRA Label

October 4, 2023 | finance.yahoo.com

Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential OTC STENDRA Label

September 28, 2023 | finance.yahoo.com

Petros Pharmaceuticals to Present at the LD Micro Main Event XVI

See More Headlines

Receive PTPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Petros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 4/01/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PTPI
CUSIP: N/A
CIK: 1815903
Web: www.petrospharma.com
Phone: 973-242-0005
Fax: N/A
Employees: 21
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.00
High Stock Price Target: $4.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +473.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($6.34)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-8,160,000.00
Net Margins: -181.87%
Pretax Margin: -140.21%
Return on Equity: -68.90%
Return on Assets: -24.74%

Debt

Debt-to-Equity Ratio: 0.57
Current Ratio: 1.89
Quick Ratio: 1.74

Sales & Book Value

Annual Sales: $5.82 million
Price / Sales: 0.83
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.04 per share
Price / Book: 0.17

Miscellaneous

Outstanding Shares: 6,880,000
Free Float: 4,375,000
Market Cap: $4.80 million
Optionable: Not Optionable
Beta: 1.91

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. John David Shulman (Age 61)
Executive Chairman of the Board
Mr. Fady Boctor M.B.A. (Age 46)
President & Chief Commercial Officer
Comp: $681.97k
Mr. Mitchell S. Arnold M.B.A. (Age 60)
VP of Finance & Chief Accounting Officer
Comp: $465.68k

Key Competitors

View All Competitors

Institutional Ownership

Virtu Financial LLC
Bought 24,825 shares on 2/26/2024
Ownership: 1.128%

View All Institutional Transactions

PTPI Stock Analysis - Frequently Asked Questions

Should I buy or sell Petros Pharmaceuticals stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Petros Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PTPI shares.
View PTPI analyst ratings or view top-rated stocks.
What is Petros Pharmaceuticals' stock price target for 2024?: 1 equities research analysts have issued 1 year target prices for Petros Pharmaceuticals' stock. Their PTPI share price targets range from $4.00 to $4.00. On average, they predict the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 473.1% from the stock's current price.
View analysts price targets for PTPI or view top-rated stocks among Wall Street analysts.
How have PTPI shares performed in 2024?: Petros Pharmaceuticals' stock was trading at $1.41 at the beginning of the year. Since then, PTPI stock has decreased by 50.5% and is now trading at $0.6979.
View the best growth stocks for 2024 here.
Are investors shorting Petros Pharmaceuticals?: Petros Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 146,200 shares, an increase of 65.4% from the March 15th total of 88,400 shares. Based on an average daily volume of 1,080,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 3.6% of the shares of the company are sold short.
View Petros Pharmaceuticals' Short Interest.

When is Petros Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our PTPI earnings forecast.
How were Petros Pharmaceuticals' earnings last quarter?: Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) announced its earnings results on Monday, April, 1st. The company reported ($2.17) EPS for the quarter. The firm had revenue of ($0.36) million for the quarter. Petros Pharmaceuticals had a negative net margin of 181.87% and a negative trailing twelve-month return on equity of 68.90%.
When did Petros Pharmaceuticals' stock split?: Petros Pharmaceuticals shares reverse split on Wednesday, November 30th 2022. The 1-10 reverse split was announced on Wednesday, November 30th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
How do I buy shares of Petros Pharmaceuticals?: Shares of PTPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PTPI) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Petros Pharmaceuticals (PTPI) Stock Price, News & Analysis

Petros Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Petros Pharmaceuticals Stock (NASDAQ:PTPI)

PTPI Stock Price History

PTPI Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

PTPI Stock Analysis - Frequently Asked Questions

Overall MarketRank^™